In vitro and in vivo assay systems for study of influenza virus inhibitors
Identifieur interne : 001951 ( Main/Exploration ); précédent : 001950; suivant : 001952In vitro and in vivo assay systems for study of influenza virus inhibitors
Auteurs : Robert W. Sidwell [États-Unis] ; Donald F. Smee [États-Unis]Source :
- Antiviral Research [ 0166-3542 ] ; 2000.
English descriptors
- KwdEn :
- Teeft :
- Academic press, Agents chemother, Amantadine, Animal model, Animal models, Anti6iral, Antimicrob, Antiviral, Antiviral activity, Antiviral assays, Antiviral chem, Antiviral compounds, Antiviral drugs, Antiviral effect, Antiviral investigators, Appropriate assay, Arterial oxygen saturation, Assay, Avian virus, Cell culture, Challenge dose, Chemother, Chick embryo, Chicken model, Clinical studies, Consolidation score, Drinking water, Drug pharmacology, Effective concentration, Elsevier science, Epithelial cells, Extracellular virus yields, Febrile response, Hayden, Huffman, Identical virus pool, Immune, Immune response, Immune system, Immunocompromised, Immunocompromised host, Infection, Infectious doses, Infectious virus, Infectivity, Inhaled zanamivir, Inhibitor, Interferon, Interferon inducers, Laboratory mouse, Lung consolidation, Lung virus titer, Lung weight, Madin darby, Major histocompatibility, Mdck cells, Mendel, Mist study group, Mouse, Mouse model, Multiple parameters, Mutant virus, Mutation, Neuraminidase, Neuraminidase inhibitor, Neuraminidase inhibitor zanamivir, Neuraminidase inhibitors, Normal controls, Oral treatment, Oseltamivir, Oseltamivir carboxylate, Parent compound, Parental virus, Plaque formation, Potential virus inhibitors, Pulse oximeter, Rate doses, Relative virulence, Replication, Respective drugs, Respiratory tract, Ribavirin, Rimantadine, Sao2, Sao2 decline, Sao2 values, Selective index, Serial passage, Sidwell, Single passage, Smee, Smee anti6iral research, Species differences, Test compound, Test compounds, Uninfected cells, Viral, Viral cytopathic effect, Viral hemagglutinin, Viral resistance, Virol, Virulence, Virus, Virus exposure, Virus infection, Virus infections, Virus neuraminidase inhibitors, Virus particles, Virus replication, Virus resistance, Virus strains, Virus susceptibility, Virus titer, Vivo, Vivo sensitivity, York acad, Zanamivir.
Abstract
Abstract: Evaluation of potential influenza virus inhibitors may utilize multiple steps. First would be to determine if the viral target (e.g. influenza virus neuraminidase) being focused upon will be inhibited in the appropriate assay. Standard in vitro antiviral assays, used next in antiviral evaluations, may utilize inhibition of viral plaques, viral cytopathic effect (CPE), and viral hemagglutinin or other protein, with inhibition of viral yield used in follow-up evaluations. The CPE can be determined visually and by dye uptake. Animal models used for study of potential influenza virus inhibitors include the ferret, the laboratory mouse, and the chicken, with a variety of parameters used to indicate the severity of the infection and its inhibition by therapy. Multiple parameters are recommended in any in vivo antiviral evaluation. The ferret and the mouse infection models have been useful in studying the development of drug resistance and the relative virulence of drug-resistant viruses. The influenza mouse model has also been of value for the evaluation of immunomodulating effects of test compounds and for the study of the utility of antiviral drugs for use against influenza virus infections in the immunocompromised host. In considering the use of any animal model, species differences in drug pharmacology and metabolism must be taken into account. This review has described the systems which have been used most frequently by antiviral investigators, using, as examples, recent studies with the clinically approved influenza virus neuraminidase inhibitors oseltamivir and zanamivir.
Url:
DOI: 10.1016/S0166-3542(00)00125-X
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001808
- to stream Istex, to step Curation: 001808
- to stream Istex, to step Checkpoint: 000766
- to stream Main, to step Merge: 001994
- to stream Main, to step Curation: 001951
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro and in vivo assay systems for study of influenza virus inhibitors</title>
<author><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W." last="Sidwell">Robert W. Sidwell</name>
</author>
<author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F." last="Smee">Donald F. Smee</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D3D663E5809BFAE4596290743862F1E678A9F78B</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1016/S0166-3542(00)00125-X</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-2HZ83H45-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001808</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001808</idno>
<idno type="wicri:Area/Istex/Curation">001808</idno>
<idno type="wicri:Area/Istex/Checkpoint">000766</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000766</idno>
<idno type="wicri:doubleKey">0166-3542:2000:Sidwell R:in:vitro:and</idno>
<idno type="wicri:Area/Main/Merge">001994</idno>
<idno type="wicri:Area/Main/Curation">001951</idno>
<idno type="wicri:Area/Main/Exploration">001951</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">In vitro and in vivo assay systems for study of influenza virus inhibitors</title>
<author><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W." last="Sidwell">Robert W. Sidwell</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, 5600 Old Main Hill., Logan, UT 84322-5600</wicri:regionArea>
<placeName><region type="state">Utah</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F." last="Smee">Donald F. Smee</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Antiviral Research, Utah State University, 5600 Old Main Hill., Logan, UT 84322-5600</wicri:regionArea>
<placeName><region type="state">Utah</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Antiviral Research</title>
<title level="j" type="abbrev">AVR</title>
<idno type="ISSN">0166-3542</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="2000">2000</date>
<biblScope unit="volume">48</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="1">1</biblScope>
<biblScope unit="page" to="16">16</biblScope>
</imprint>
<idno type="ISSN">0166-3542</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Influenza</term>
<term>Oseltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Academic press</term>
<term>Agents chemother</term>
<term>Amantadine</term>
<term>Animal model</term>
<term>Animal models</term>
<term>Anti6iral</term>
<term>Antimicrob</term>
<term>Antiviral</term>
<term>Antiviral activity</term>
<term>Antiviral assays</term>
<term>Antiviral chem</term>
<term>Antiviral compounds</term>
<term>Antiviral drugs</term>
<term>Antiviral effect</term>
<term>Antiviral investigators</term>
<term>Appropriate assay</term>
<term>Arterial oxygen saturation</term>
<term>Assay</term>
<term>Avian virus</term>
<term>Cell culture</term>
<term>Challenge dose</term>
<term>Chemother</term>
<term>Chick embryo</term>
<term>Chicken model</term>
<term>Clinical studies</term>
<term>Consolidation score</term>
<term>Drinking water</term>
<term>Drug pharmacology</term>
<term>Effective concentration</term>
<term>Elsevier science</term>
<term>Epithelial cells</term>
<term>Extracellular virus yields</term>
<term>Febrile response</term>
<term>Hayden</term>
<term>Huffman</term>
<term>Identical virus pool</term>
<term>Immune</term>
<term>Immune response</term>
<term>Immune system</term>
<term>Immunocompromised</term>
<term>Immunocompromised host</term>
<term>Infection</term>
<term>Infectious doses</term>
<term>Infectious virus</term>
<term>Infectivity</term>
<term>Inhaled zanamivir</term>
<term>Inhibitor</term>
<term>Interferon</term>
<term>Interferon inducers</term>
<term>Laboratory mouse</term>
<term>Lung consolidation</term>
<term>Lung virus titer</term>
<term>Lung weight</term>
<term>Madin darby</term>
<term>Major histocompatibility</term>
<term>Mdck cells</term>
<term>Mendel</term>
<term>Mist study group</term>
<term>Mouse</term>
<term>Mouse model</term>
<term>Multiple parameters</term>
<term>Mutant virus</term>
<term>Mutation</term>
<term>Neuraminidase</term>
<term>Neuraminidase inhibitor</term>
<term>Neuraminidase inhibitor zanamivir</term>
<term>Neuraminidase inhibitors</term>
<term>Normal controls</term>
<term>Oral treatment</term>
<term>Oseltamivir</term>
<term>Oseltamivir carboxylate</term>
<term>Parent compound</term>
<term>Parental virus</term>
<term>Plaque formation</term>
<term>Potential virus inhibitors</term>
<term>Pulse oximeter</term>
<term>Rate doses</term>
<term>Relative virulence</term>
<term>Replication</term>
<term>Respective drugs</term>
<term>Respiratory tract</term>
<term>Ribavirin</term>
<term>Rimantadine</term>
<term>Sao2</term>
<term>Sao2 decline</term>
<term>Sao2 values</term>
<term>Selective index</term>
<term>Serial passage</term>
<term>Sidwell</term>
<term>Single passage</term>
<term>Smee</term>
<term>Smee anti6iral research</term>
<term>Species differences</term>
<term>Test compound</term>
<term>Test compounds</term>
<term>Uninfected cells</term>
<term>Viral</term>
<term>Viral cytopathic effect</term>
<term>Viral hemagglutinin</term>
<term>Viral resistance</term>
<term>Virol</term>
<term>Virulence</term>
<term>Virus</term>
<term>Virus exposure</term>
<term>Virus infection</term>
<term>Virus infections</term>
<term>Virus neuraminidase inhibitors</term>
<term>Virus particles</term>
<term>Virus replication</term>
<term>Virus resistance</term>
<term>Virus strains</term>
<term>Virus susceptibility</term>
<term>Virus titer</term>
<term>Vivo</term>
<term>Vivo sensitivity</term>
<term>York acad</term>
<term>Zanamivir</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Evaluation of potential influenza virus inhibitors may utilize multiple steps. First would be to determine if the viral target (e.g. influenza virus neuraminidase) being focused upon will be inhibited in the appropriate assay. Standard in vitro antiviral assays, used next in antiviral evaluations, may utilize inhibition of viral plaques, viral cytopathic effect (CPE), and viral hemagglutinin or other protein, with inhibition of viral yield used in follow-up evaluations. The CPE can be determined visually and by dye uptake. Animal models used for study of potential influenza virus inhibitors include the ferret, the laboratory mouse, and the chicken, with a variety of parameters used to indicate the severity of the infection and its inhibition by therapy. Multiple parameters are recommended in any in vivo antiviral evaluation. The ferret and the mouse infection models have been useful in studying the development of drug resistance and the relative virulence of drug-resistant viruses. The influenza mouse model has also been of value for the evaluation of immunomodulating effects of test compounds and for the study of the utility of antiviral drugs for use against influenza virus infections in the immunocompromised host. In considering the use of any animal model, species differences in drug pharmacology and metabolism must be taken into account. This review has described the systems which have been used most frequently by antiviral investigators, using, as examples, recent studies with the clinically approved influenza virus neuraminidase inhibitors oseltamivir and zanamivir.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Utah</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Utah"><name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W." last="Sidwell">Robert W. Sidwell</name>
</region>
<name sortKey="Sidwell, Robert W" sort="Sidwell, Robert W" uniqKey="Sidwell R" first="Robert W." last="Sidwell">Robert W. Sidwell</name>
<name sortKey="Smee, Donald F" sort="Smee, Donald F" uniqKey="Smee D" first="Donald F." last="Smee">Donald F. Smee</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001951 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001951 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:D3D663E5809BFAE4596290743862F1E678A9F78B |texte= In vitro and in vivo assay systems for study of influenza virus inhibitors }}
This area was generated with Dilib version V0.6.33. |